In Depth 3 Jul 2025 Revolutionizing glioblastoma treatment: How CAR-T cell therapy could represent a cure for this deadly brain cancer Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could potentially cure glioblastoma. July 3, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Reports Produced by Inpart 19 May 2025Oncology R&D trends and breakthrough innovations Explore the latest in oncology R&D with Inpart’s new trends report, featuring emerging technologies, breakthrough innovations, and expert insights shaping the future of cancer research. May 19, 2025 Share WhatsApp Twitter Linkedin Email Produced by Inpart
News and Trends 24 May 2023 Major progress as Swedish scientists get brain tumors to self destruct Researchers at the University of Gothenburg in Sweden, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma. By blocking certain functions in the cell with a docked molecule, the researchers cause the cancer to die of stress.Cancer cells, especially those that form aggressive tumors, are in one […] May 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 May 2023 Five advancements in brain tumor research over the past year In 2023, it is estimated that 24,810 adults in the U.S. will be diagnosed with a primary malignant tumor of the brain and spinal cord. There is currently no cure for brain tumors and current treatment options are mostly limited to surgery, radiation therapy and chemotherapy. However, there is a lot of research being conducted […] May 16, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Research looks to make drug appear like brain tumor ‘food’ New research has shown that the blood vessels that feed aggressive brain tumors have receptors that could allow a new type of drug-containing nanoparticle to be used to starve the tumors of the energy they use to grow and spread, and also cause other disruptions to their adapted existence, even killing themselves. Scientists from the […] March 8, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 New drug could replace current standard for treating brain cancer Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […] January 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2022 Researchers identify gene alterations that may affect response to brain cancer treatment Spanish researchers have identified a range of genetic alterations in glioma brain cancers that will help them to understand how different mutations in one particular gene interact with other gene alterations and which ones are more susceptible to targeted treatments in adults. Presenting results from the largest group of glioma patients to date, Karisa Schreck […] October 28, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Study data for glioblastoma treatment confirms safety and tolerability profile The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […] September 22, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Cancer drug for children and young people with glioblastoma given to patients in study Clinical-stage bio company, Onxeo, has announced that the first patients have been enrolled and treated in a phase 1b/2 clinical study. The study is to evaluate the efficacy and tolerability of AsiDNA2, a DDR inhibitor combined with radiotherapy in children, adolescents or young adults with relapsed high grade glioma (HGG). Onxeo, which focuses on drugs […] September 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 New discovery could lead to drug development for brain cancer According to researchers, a study at Tel Aviv University in Israel effectively eradicated glioblastoma, a highly lethal type of brain cancer. The researchers achieved the outcome using a method they developed based on their discovery of two critical mechanisms in the brain that support tumor growth and survival: one protects cancer cells from the immune […] September 1, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Nov 2019 US-French Deal to Tailor Ultrasound Therapy to Brain Cancer Patients The French company CarThera has teamed up with the US firm Kiyatec to study the effects on individual patients of an ultrasound therapy to deliver brain cancer drugs to the brain. Under the agreement, Kiyatec will test the effects of chemotherapy on cells taken from CarThera’s ongoing phase I/II trial in patients with brain cancer. […] November 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Nov 2019 UK Scientists Speed up Brain Cancer Diagnosis with AI A technique combining a blood test with artificial intelligence (AI), developed by the UK company ClinSpec Diagnostics, could help to prioritize which patients need to be scanned for brain cancer. A team led by researchers at the University of Strathclyde and the University of Edinburgh, UK, trialed the technology on blood samples from 400 people […] November 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email